The Angie Project is a clinically oriented targeted drug-delivery platform designed to support controlled navigation and localised therapeutic release within complex vascular environments.
Modern medicine can often identify disease with remarkable precision through imaging, diagnostics, and data-driven analysis. Delivering therapy with the same level of control and accuracy remains a major challenge in targeted drug delivery.
Many treatments still rely on systemic administration, in which therapeutic agents circulate throughout the body before reaching the intended target site.
While necessary in many clinical contexts, this approach can increase systemic exposure and contribute to unwanted side effects.
Rather than relying on passive distribution, therapy must reach intricate vascular pathways and hard-to-access regions inside the body.
The system is designed for more precise delivery through externally controlled movement and targeted localisation.
Delivering the right dose precisely where it is needed — without exposing the whole body — remains the core difficulty.
Higher systemic exposure is a major driver of unwanted side effects.
The platform is externally guided throughout the navigation process.
Movement is monitored using imaging-supported systems with a safety-first approach.
The objective is controlled, localised therapeutic delivery under medically relevant conditions.
Because advanced targeted drug-delivery systems can sometimes be misunderstood or subject to speculative interpretations, the Angie Project places a strong emphasis on control, monitoring, and scientific transparency.
Designed to move through complex biological environments while maintaining controlled navigation and localised therapeutic release.
The Angie Project continues to evolve through long-term research, scientific collaboration, and ongoing work toward clinical translation. Connect with the team to learn more.